Your browser doesn't support javascript.
loading
Lung and digestive neuroendocrine neoplasms. From WHO classification to biomarker screening: Which perspectives?
Scoazec, Jean-Yves.
Afiliación
  • Scoazec JY; Department of pathology, Gustave-Roussy Cancer Campus, 114, rue Edouard-Vaillant, 94805 Villejuif cedex, France; Faculté de médecine de Bicêtre, université Paris Sud, 94270 Le Kremlin-Bicêtre, France. Electronic address: jean-yves.scoazec@gustaveroussy.fr.
Ann Endocrinol (Paris) ; 80(3): 163-165, 2019 Jun.
Article en En | MEDLINE | ID: mdl-31064659
The recent classifications of lung and digestive neuroendocrine neoplasms (NENs) make a fundamental distinction between well- and poorly-differentiated neoplasms. Well-differentiated NENs are termed carcinoids in the lung and neuroendocrine tumors in the gastroenteropancreatic sphere; their risk of malignancy is highly variable; histological grading is used to stratify patients into prognostically significant groups. Poorly-differentiated NENs are termed neuroendocrine carcinoma in both the lung and the digestive sphere; they constantly are of high grade of malignancy; two types are recognized on the basis of tumor cell morphology, the small cell and the large cell types. Recent studies have largely uncovered the genetic landscape of several subsets of well-differentiated NENs (lung, pancreas, small intestine) and of poorly-differentiated NENs. Some molecular markers may help to the differential diagnosis between highly proliferative neuroendocrine tumors and neuroendocrine carcinomas, especially in the pancreas. In well-differentiated tumors, MGMT status is proposed as a predictive marker of the response to temozolomide, but remains to be validated. In poorly-differentiated neoplasms, large cell neuroendocrine carcinoma has been shown to be a heterogeneous category, with some cases presenting the same molecular signature than small cell carcinoma and others the same signature than adenocarcinomas of the same body site. Rb protein has been recently shown to be a potential marker of response to platinum salts in neuroendocrine carcinoma. Much remains to be done to translate the rapid progress in the molecular understanding of NENS into diagnostic, prognostic or predictive markers.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Organización Mundial de la Salud / Biomarcadores de Tumor / Tumores Neuroendocrinos / Neoplasias del Sistema Digestivo / Neoplasias Pulmonares Tipo de estudio: Diagnostic_studies / Prognostic_studies / Screening_studies Límite: Humans Idioma: En Revista: Ann Endocrinol (Paris) Año: 2019 Tipo del documento: Article Pais de publicación: Francia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Organización Mundial de la Salud / Biomarcadores de Tumor / Tumores Neuroendocrinos / Neoplasias del Sistema Digestivo / Neoplasias Pulmonares Tipo de estudio: Diagnostic_studies / Prognostic_studies / Screening_studies Límite: Humans Idioma: En Revista: Ann Endocrinol (Paris) Año: 2019 Tipo del documento: Article Pais de publicación: Francia